论文部分内容阅读
干扰素(IFN)是建立多方面抗病毒反应的关键因子,基于其受体、结构特性和生物活性公认有三种不同的类型的IFN(1型、2型和3型)。IFN-λ是一个新近发现的在体外和体内都能引发抗病毒反应的细胞因子,与受体结合可以诱导受体异二聚体化,导致Janus激酶-信号转导子和转录激活子(JAK-STAT)信号转导途径的激活,发挥与1型干扰素相似的抗病毒生物学效应,如调节Th1、Th2及疾病治疗等。在乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、人类免疫缺陷病毒(HIV)和人类疱疹病毒-6B(HHV-6B)等治疗上有很大的影响,而且其副作用比1型干扰素低,为IFN-λ的临床应用研究提供了新思路。
Interferon (IFN) is a key factor in establishing a multifaceted antiviral response, and three different types of IFNs (Type 1, Type 2 and Type 3) are recognized based on their receptors, structural properties and biological activity. IFN-λ is a newly discovered cytokine that can trigger antiviral responses both in vitro and in vivo. Binding to the receptor induces heterodimerization of the receptor, leading to Janus kinase-signal transducers and activators of transcription (JAK -STAT) signal transduction pathway, play an anti-virus biological effects similar to type 1 interferon, such as regulating Th1, Th2 and disease treatment. Hepatitis B virus (HCV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and human herpesvirus-6B (HHV-6B) and other treatment has a great impact, and its side effects than type 1 Low interferon provides a new idea for the clinical application of IFN-λ.